Your browser doesn't support javascript.
loading
A Novel and Expanding SARS-CoV-2 Variant, B.1.1.318, dominates infections in Mauritius
Houriiyah Tegally; Magalutcheemee Ramuth; Daniel Amoaka; Cathrine Scheepers; Eduan Wilkinson; Marta Giovanetti; Richard J Lessells; Jennifer Giandhari; Arshad Ismail; Darren Martin; Emmanuel James San; Margaret Crawford; Rodney S Daniels; Ruth Harvey; Somduthsingh Bahadoor; Janaki Sonoo; Myriam Timol; Lovena Veerapa-Mangroo; Anne von Gottberg; Jinal Bhiman; Tulio de Oliveira; Shyam Manraj.
Affiliation
  • Houriiyah Tegally; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Magalutcheemee Ramuth; Central Health Laboratory, Victoria Hospital, Candos, Mauritius
  • Daniel Amoaka; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Cathrine Scheepers; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Eduan Wilkinson; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Marta Giovanetti; Laboratorio de Flavivirus, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil
  • Richard J Lessells; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Jennifer Giandhari; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Arshad Ismail; Division of Computational Biology, Department of Integrative Biomedical Sciences, Institute of Infectious Diseases and Molecular medicine, The University of Cap
  • Darren Martin; Division of Computational Biology, Department of Integrative Biomedical Sciences, Institute of Infectious Diseases and Molecular medicine, The University of Cap
  • Emmanuel James San; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Margaret Crawford; Advanced Sequencing Facility, The Francis Crick Institute, London, United Kingdom
  • Rodney S Daniels; Worldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom
  • Ruth Harvey; Worldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom
  • Somduthsingh Bahadoor; Central Health Laboratory, Victoria Hospital, Candos, Mauritius
  • Janaki Sonoo; Central Health Laboratory, Victoria Hospital, Candos, Mauritius
  • Myriam Timol; Ministry of Health and Wellness, Port Louis, Mauritius
  • Lovena Veerapa-Mangroo; Ministry of Health and Wellness, Port Louis, Mauritius
  • Anne von Gottberg; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Jinal Bhiman; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Tulio de Oliveira; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Shyam Manraj; Central Health Laboratory, Victoria Hospital, Candos, Mauritius
Preprint in English | medRxiv | ID: ppmedrxiv-21259017
ABSTRACT
Mauritius, a small island in the Indian Ocean, has had a unique experience of the SARS-CoV-2 pandemic. In March 2020, Mauritius endured a small first wave and quickly implemented control measures which allowed elimination of local transmission of SARS-CoV-2. When borders to the island reopened, it was accompanied by mandatory quarantine and testing of incoming passengers to avoid reintroduction of the virus into the community. As variants of concern (VOCs) emerged elsewhere in the world, Mauritius began using genomic surveillance to keep track of quarantined cases of these variants. In March 2021, another local outbreak occurred, and sequencing was used to investigate this new wave of local infections. Here, we analyze 154 SARS-CoV-2 viral genomes from Mauritius, which represent 12% of all the infections seem in Mauritius, these were both from specimens of incoming passengers before March 2021 and those of cases during the second wave. Our findings indicate that despite the presence of known VOCs Beta (B.1.351) and Alpha (B.1.1.7) among quarantined passengers, the second wave of local SARS-CoV-2 infections in Mauritius was caused by a single introduction and dominant circulation of the B.1.1.318 virus. The B.1.1.318 variant is characterized by fourteen non-synonymous mutations in the S-gene, with five encoded amino acid substitutions (T95I, E484K, D614G, P681H, D796H) and one deletion (Y144del) in the Spike glycoprotein. This variant seems to be increasing in prevalence and it is now present in 34 countries. This study highlights that despite having stopped the introduction of more transmissible VOCs by travel quarantines, a single undetected introduction of a B.1.1.318 lineage virus was enough to initiate a large local outbreak in Mauritius and demonstrated the need for continuous genomic surveillance to fully inform public health decisions.
License
cc_by_nc_nd
Full text: Available Collection: Preprints Database: medRxiv Type of study: Observational study Language: English Year: 2021 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Observational study Language: English Year: 2021 Document type: Preprint
...